Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia - PubMed (original) (raw)
Comparative Study
. 2002 May 15;20(10):2480-5.
doi: 10.1200/JCO.2002.08.155.
Affiliations
- PMID: 12011125
- DOI: 10.1200/JCO.2002.08.155
Comparative Study
Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia
Stefan Fröhling et al. J Clin Oncol. 2002.
Abstract
Purpose: To prospectively compare cytogenetic and molecular cytogenetic analysis for the detection of the most relevant chromosome abnormalities in a large series of patients with acute myeloid leukemia (AML).
Patients and methods: Two hundred forty consecutive adult patients with AML entered onto the multicenter treatment trial AML HD93 were studied. Chromosome banding and fluorescence in situ hybridization (FISH) applying a comprehensive set of genomic DNA probes were performed in a single reference laboratory.
Results: Two cases of inv(16), three cases of t(11q23), and three cases of t(8;21)var were only detected by molecular cytogenetics. By FISH, aberrations were identified in three cases with normal karyotypes: inv(16), -Y (in a patient with low metaphase yield on chromosome banding) and a 12p microdeletion. Additional aneuploidies, in particular +8q and +11q, were diagnosed by FISH; however, virtually all these aberrations occurred in patients with complex karyotypes or as an additional abnormality in leukemias with an AML-specific translocation. Finally, aberrations were detected by FISH in eight of 14 patients with no assessable metaphases.
Conclusion: In most cases of AML, conventional cytogenetic study reliably detects chromosomal abnormalities, and this method should not be replaced by FISH. FISH should be used as a complementary method for the detection of more subtle abnormalities, such as inv(16) and t(11q23), in all patients with newly diagnosed AML and for suspected t(8;21)var. Furthermore, molecular cytogenetics using this comprehensive set of DNA probes provides a valuable diagnostic tool for patients with poor chromosome morphology, low or no yields of metaphase cells, or both.
Similar articles
- Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia.
Fischer K, Scholl C, Sàlat J, Fröhling S, Schlenk R, Bentz M, Stilgenbauer S, Lichter P, Döhner H. Fischer K, et al. Blood. 1996 Nov 15;88(10):3962-71. Blood. 1996. PMID: 8916963 - Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia.
Fröhling S, Kayser S, Mayer C, Miller S, Wieland C, Skelin S, Schlenk RF, Döhner H, Döhner K; AML Study Group Ulm. Fröhling S, et al. Haematologica. 2005 Feb;90(2):194-9. Haematologica. 2005. PMID: 15710571 - Usefulness of cytogenetics in leukemias.
VinSheth FJ, Sheth JJ, Patel AI, Shah AD, Verhest A. VinSheth FJ, et al. Indian J Cancer. 2002 Oct-Dec;39(4):139-42. Indian J Cancer. 2002. PMID: 12928572 - Multicolor karyotyping in acute myeloid leukemia.
Tchinda J, Volpert S, McNeil N, Neumann T, Kennerknecht I, Ried T, Büchner T, Serve H, Berdel WE, Horst J, Hilgenfeld E. Tchinda J, et al. Leuk Lymphoma. 2003 Nov;44(11):1843-53. doi: 10.1080/10428190310001603605. Leuk Lymphoma. 2003. PMID: 14738135 Review.
Cited by
- Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption.
Morin S, Giannotti F, Mamez AC, Pradier A, Masouridi-Levrat S, Simonetta F, Chalandon Y. Morin S, et al. Front Oncol. 2023 Mar 15;13:1095870. doi: 10.3389/fonc.2023.1095870. eCollection 2023. Front Oncol. 2023. PMID: 37007116 Free PMC article. - Role of Biomarkers in FLT3 AML.
Nitika, Wei J, Hui AM. Nitika, et al. Cancers (Basel). 2022 Feb 24;14(5):1164. doi: 10.3390/cancers14051164. Cancers (Basel). 2022. PMID: 35267471 Free PMC article. Review. - Expression of immune check point gene TIM-3 in patients newly diagnosed with acute myeloid leukemia: Significance and impact on outcome.
Kamal AM, Nabih NA, Elleboudy NS, Radwan SM. Kamal AM, et al. Oncol Lett. 2021 Apr;21(4):325. doi: 10.3892/ol.2021.12587. Epub 2021 Feb 24. Oncol Lett. 2021. PMID: 33692857 Free PMC article. - Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML.
Mareschal S, Palau A, Lindberg J, Ruminy P, Nilsson C, Bengtzén S, Engvall M, Eriksson A, Neddermeyer A, Marchand V, Jansson M, Björklund M, Jardin F, Rantalainen M, Lennartsson A, Cavelier L, Grönberg H, Lehmann S. Mareschal S, et al. Blood Adv. 2021 Feb 23;5(4):1003-1016. doi: 10.1182/bloodadvances.2020002517. Blood Adv. 2021. PMID: 33591326 Free PMC article. - MRD Tailored Therapy in AML: What We Have Learned So Far.
Ngai LL, Kelder A, Janssen JJWM, Ossenkoppele GJ, Cloos J. Ngai LL, et al. Front Oncol. 2021 Jan 15;10:603636. doi: 10.3389/fonc.2020.603636. eCollection 2020. Front Oncol. 2021. PMID: 33575214 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources